WO1999011795A1 - Materiels de proteine-kinase point de controle du cycle cellulaire, effecteur de chk1 mammalien et methodes - Google Patents

Materiels de proteine-kinase point de controle du cycle cellulaire, effecteur de chk1 mammalien et methodes Download PDF

Info

Publication number
WO1999011795A1
WO1999011795A1 PCT/US1998/018558 US9818558W WO9911795A1 WO 1999011795 A1 WO1999011795 A1 WO 1999011795A1 US 9818558 W US9818558 W US 9818558W WO 9911795 A1 WO9911795 A1 WO 9911795A1
Authority
WO
WIPO (PCT)
Prior art keywords
chkl
dna
kinase
seq
cell
Prior art date
Application number
PCT/US1998/018558
Other languages
English (en)
Inventor
Antony Michael Carr
Original Assignee
Icos Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corporation filed Critical Icos Corporation
Priority to CA002270911A priority Critical patent/CA2270911A1/fr
Priority to AU92231/98A priority patent/AU9223198A/en
Priority to JP51710899A priority patent/JP2002516577A/ja
Priority to EP98944772A priority patent/EP0960203A1/fr
Publication of WO1999011795A1 publication Critical patent/WO1999011795A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Definitions

  • the present invention generally cell cycle checkpoint protein kinases which are essential to cellular DNA damage responses and coordinating cell cycle arrest.
  • the checkpoint kinases play a role in the surveillance and response to DNA damage that occurs as a result of replication errors, DNA mismatches, radiation treatment, or chemotherapy. These checkpoint kinases are required in regulatory pathways that lead to cell cycle arrest and apoptosis following DNA damage, giving the cell notice and time to correct lesions prior to the initiation of DNA replication or chromosome separation.
  • the present invention relates to novel mammalian effector (Chkl) checkpoint protein kinases, polynucleotides encoding the same, and methods and materials for assaying and modulating the enzymatic activity of the kinases.
  • Chokl mammalian effector
  • the cell cycle is structurally and functionally conserved in its basic process and mode of regulation across all eukaryotic species.
  • the process of eukaryotic cell growth and division is the somatic (mitotic) cell cycle which consists of four phases, the
  • the Gl phase is collectively referred to as interphase of the cell cycle.
  • the S (synthesis) phase begins when DNA synthesis starts and ends when the DNA content of the nucleus of the cell has been replicated and two identical sets of chromosomes are formed.
  • the cell then enters the G2 (gap) phase which continues until mitosis starts.
  • mitosis the chromosomes pair and separate and two new nuclei form, and in cytokinesis, the cell itself splits into two daughter cells each receiving one nucleus containing one of the two sets of chromosomes. Mitosis (the M phase of the cell cycle) is immediately followed by cytokinesis.
  • Cytokines terminates the M phase and marks the beginning of interphase of the next cell cycle.
  • the sequence in which the events in the cell cycle proceed is tightly regulated such that the initiation of one cell cycle event is dependent on the completion of the prior cell cycle event. This allows fidelity in the duplication and segregation of genetic material from one generation of somatic cells to the next.
  • Meiosis is the form of cell division that produces germ cells in higher eukaryotes. In contrast to mitosis, where mitotic cell division results in genetically identical cells containing two of each chromosome, meiotic cell division results in cells containing one copy of each chromosome. In addition, in meiosis homologous chromosomes pair and exchange genetic material. Meiosis consists of two stages of cell division, meiosis I and meiosis II. In meiosis I, maternal and paternal chromosomes duplicate and homologous chromosomes pair together (synapsis).
  • the cell then undergoes division in which homologous pairs of duplicate chromosomes separate and enter individual cells resulting in two diploid daughter cells.
  • the daughter cells then enter meiosis II.
  • meiosis II the chromosomes align without further replication and sister chromatids separate, as in mitosis, to produce haploid cells.
  • the sequence of events in both meiosis I and meiosis II are interphase, prophase, metaphase, anaphase, and telophase.
  • the first stage of meiosis I is interphase I in which each chromosome is replicated.
  • the two copies of the replicated chromosome are called sister chromatids.
  • Five sequential stages then define the first meiotic prophase.
  • the newly replicated sister chromatids are in close apposition so that they may associate and undergo recombination.
  • a proteinaceous structure termed the synaptonemal complex forms between maternal sister chromatids and paternal sister chromatids resulting in a bivalent (four chromatids).
  • pachytene recombination between two sister chromatids (i.e.
  • Cell cycle checkpoints consist of signal transduction cascades which couple DNA damage detection to cell cycle progression. In meiosis, cell cycle checkpoints control programmed DNA breaks, ensuring the proper segregation of a complete haploid set of chromosomes to each gamete. Failure of cell cycle checkpoints predisposes individuals to or directly causes many disease states such as cancer, ataxia telangiectasia, embryo abnormalities, and various immunological defects associated with aberrant B and T cell development. The latter are associated with pathological states such as lupus, arthritis and autoimmune diseases. Intense research efforts have therefore focused on identifying cell cycle checkpoints and the proteins essential for the function of the checkpoints.
  • cell cycle checkpoints comprise at least three distinct classes of polypeptides which act sequentially in response to cell cycle signals or defects in chromosomal mechanisms. [Carr, A.M., Science, 271:314-315 (1996)].
  • the first class is a family of proteins which detect or sense DNA damage or abnormalities in the cell cycle. These sensors include Atm and Atr [Keegan et al., Genes and Devel.,
  • the second class of polypeptides amplify and transmit the signal detected by the detector and is exemplified by Rad53 [Alen et al. (1994) Genes Dev. 8:2416-2488].
  • the cell cycle checkpoint effects a cellular response, e.g. arrest of mitosis/meiosis, apoptosis through cell cycle effectors.
  • Saccharomyces cerevisiae has identified a number of checkpoint genes important for mitotic arrest and DNA repair responses to IR. For a review, see Carr and Hoekstra, Trends in Cell Biology, 5: 32-40 (1995).
  • One such gene, identified in yeasts is required for a DNA damage checkpoint which arrests mitosis at the G2 phase, as well as a related checkpoint which monitors the completion of DNA synthesis and arrests the cell cycle at the S phase.
  • the gene is named rad3 in S. pombe [Seaton et al., Gene, 119: 83-89 (1992) Bentley et al., (1996) EM BO J. 15: 6641-6651], MEC1 ESR1 in S.
  • rad3 Cells having mutations in rad3 fail to either sense or appropriately respond to DNA damage and subsequently lose viability more rapidly than wild type cells after exposure to clastogenic agents or events (e.g., IR, DNA damaging agents, and mutations affecting chromosomal integrity). See Weinert et al., GENES & DEVELOPMENT, 8: 652-665 (1994) and Al-Khodairy et al., EMBO J., 11(4): 1343-1350 (1992).
  • Rad3 thus appears to be a checkpoint detector of DNA damage (Carr, 1996).
  • rad3 appears to function in vivo as a multimer. [Bentley et al., 1996].
  • the product of the rad3 gene is an approximately 270 kD protein that is a member of a growing family of high molecular weight mammalian checkpoint kinases. See Hunter, Cell, 83: 1-4 (1995) for a discussion of this family of kinases. This family includes ecll (S. cerevisiae) mei-41 (Drosophila melanogaster), tori (S. cerevisiae), tor2 (S. cerevisiae), Frap (Human), tell (S. cerevisiae), DNA-Pk (Human) Atr (human) and Atm (human). These proteins have been identified as members of a family based on sequence homology and complementation studies.
  • the primary structures of the catalytic domains found in members of this kinase family are closely related to well characterized phosphatidylinositol kinases. This structural relationship initially suggested that these mammalian checkpoint kinases might be capable of phosphorylating lipids. However, when the substrate specificity of the mammalian checkpoint kinases is examined, these enzymes appear to function as protein kinases and have yet to be demonstrated to phosphorylate phosphatidylinositides.
  • Atm Ataxia Telangiectasia Mutated
  • AT human disease syndrome ataxia-telangiectasia
  • S. pombe stains with rad3 defects where cells fail to sense or respond appropriately to DNA damage.
  • Atm and Atr proteins associate with chromosomes during pachynema of meiotic prophase and may monitor strand disruptions that occur during meiotic chromosome synapsis and recombination.
  • Atm and Atr kinases show complementary patterns of foci during zygonema and pachynema, commensurate with different roles in monitoring the DNA structure during meiotic recombination [Keegan et al., Genes Dev., 10:2423 (1996)].
  • Atm and Atr are protein kinases that comprise a early step in the signal transduction cascade. It is thought that signally is amplified by protein kinases such as Rad53 which acts to transduce a signal from the detectors to the effectors.
  • S. pombe Chkl and weel have been identified as effector checkpoint proteins.
  • the S. pombe Chkl gene was isolated based on its genetic interaction with the cdc2.r4 allele [Al-Khodairy et al., Mol. Biol. Cell, 5:147-160 (1994)], and by complementation of the radiation sensitivity of a rad27 mutant.
  • cdc2 encodes a protein kinase subunit that associates with cyclins to form active protein kinase complexes that induce passage through mitosis. [Broek et al., Nature, 349:388-393 (1991].
  • pombe Chkl appears to effect the mitotic arrest following DNA damage and S. pombe Chkl deletion mutants fail to undergo cell-cycle arrest after irradiation [Walworth et al. , Nature, 363:368 (1993), Al-Khodairy et al., Mol. Biol. Cell., 5:147-160 (1994), Carr, A.M., Semin. Cell Biol., 6:65-72 (1995)].
  • Chkl is not required for the other checkpoint protein-mediated DNA cellular responses to blocks to DNA replication. Walworth and Bernards Science, 271 :353-356 (1996) demonstrated that in vivo activity of Chkl is regulated by phosphorylation of Chkl.
  • Grp is required for cell cycle control at the mid-blastula transition (MBT) in which the maternal component of the DNA-replication machinery slows DNA synthesis and induces a checkpoint-dependent delay in cell cycle progression during embryogenesis.
  • MCT mid-blastula transition
  • the C. elegans homolog of Chkl was first reported as an EST in Genbank
  • the present invention provides novel human mammalian effector cell cycle checkpoint, Chkl, kinases and polynucleotides encoding the same.
  • the present invention provides purified and isolated polynucleotides (e.g., DNAs and RNAs, both coding and non-coding strands thereof) encoding the human and mouse effector cell cycle checkpoint kinase and polynucleotides encoding other mammalian checkpoint kinases that exhibit 50% or greater amino acid identity to the polynucleotide region encoding the human Chkl kinase domain (amino acids 14 to 264 of SEQ ID NO.: 2).
  • the polynucleotides encode a checkpoint kinase that exhibits 70% or greater amino acid identity to amino acids 14 to 264 of SEQ ID NO.: 2.
  • polynucleotides encode a checkpoint kinase that exhibits 90% or greater amino acid identity to amino acids 14 to 264 of SEQ ID NO.: 2.
  • Polynucleotides contemplated by the invention include genomic DNAs, RNAs, cDNAs and wholly or partially chemically synthesized DNAs.
  • Preferred polynucleotides of the invention comprise the human Chkl DNA sequence set out in SEQ LD NO.: 1, the mouse Chkl DNA sequence set out in SEQ LD NO. : 3, and DNA sequences which hybridize to the noncoding strands thereof under stringent conditions or which would hybridize but for the redundancy of the genetic code.
  • Exemplary stringent hybridization conditions are as follows: hybridization at 65° C in 3X SSC, 20 mM NaPO 4 pH 6.8 and washing at 65° C in 0.2X SSC. It is understood by those of skill in the art that variation in these conditions occurs based on the length and GC nucleotide base content of the sequences to be hybridized. Formulas standard in the art are appropriate for determining exact hybridization conditions. See Sambrook et al., 9.47-9.51 in Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).
  • Plasmid pGEMT-Chklhu A polynucleotide vector encoding human Chkl (plasmid pGEMT-Chklhu ) was deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852 on date August 27, 1997 under Accession No. ATCC98520.
  • the DNA sequence information provided by the present invention makes possible the identification and isolation of DNAs encoding mammalian checkpoint related molecules by well-known techniques such as DNA/DNA hybridization as described above and polymerase chain reaction (PCR) cloning.
  • PCR polymerase chain reaction
  • knowledge of the sequence of a cDNA encoding a mammalian Chkl of the invention makes possible the isolation by DNA/DNA hybridization of genomic DNA sequences encoding the kinase and expression control regulatory sequences such as promoters, operators and the like.
  • knowledge of a partial cDNA sequence makes isolation of a complete cDNA possible.
  • DNA/DNA hybridization procedures carried out with DNA sequences of the invention under stringent conditions are likewise expected to allow the isolation of DNAs encoding allelic variants of the kinase non-human species enzymes homologous to the mammalian Chkl kinase and other structurally related proteins sharing one or more of the enzymatic activities, or abilities to interact with members or regulators, of the cell cycle checkpoint pathway in which mammalian Chkl participates.
  • Polynucleotides of the invention when detectably labeled are also useful in hybridization assays to detect the capacity of mammalian cells to synthesize kinases of the invention.
  • the DNA sequence information provided by the present invention also makes possible the development, by homologous recombination or "knockout” strategies [see, Capecchi, Science, 244: 1288-1292 (1989)], of rodents that fail to express a functional kinase or that express a variant thereof. Such rodents and their cells are useful as models for studying the activities of mouse and kinase modulators in vivo.
  • Polynucleotides of the invention may also be the basis for diagnostic methods useful for identifying a genetic alteration(s) in the mammalian Chkl gene locus that underlies a disease state or states. Also made available by the invention are anti-sense polynucleotides relevant to regulating expression of Chkl by those cells which ordinarily express the same.
  • primers designed from the Chkl cDNA are useful for reverse transcriptase PCR analysis of mRNA samples from tumor cells to detect the presence or absence of Chkl mRNA.
  • sequence information from the Chkl genomic clone can be used for single stranded conformational polymorphism (SSCP) analysis of genomic DNA prepared from tumor cells to detect alterations or mutations of the Chkl gene.
  • SSCP single stranded conformational polymorphism
  • the Chkl cDNA and/or the Chkl genomic clone can be used in fluorescence in situ hybridization (FISH) analysis to detect alterations in the Chkl gene.
  • FISH fluorescence in situ hybridization
  • the invention also provides autonomously replicating recombinant constructions such as plasmid and viral DNA vectors incorporating polynucleotides of the invention, especially vectors in which the polynucleotides are functionally linked to an endogenous or heterologous expression control DNA sequence and a transcription terminator.
  • host cells especially unicellular host cells such as procaryotic and eukaryotic cells, are stably transformed or transfected with DNAs of the invention in a manner allowing expression of a mammalian cells
  • Chkl kinase therein.
  • Host cells of the invention are conspicuously useful in methods for the large scale production of Chkl wherein the cells are grown in a suitable culture medium and the desired enzymes are isolated from the cells or from the medium in which the cells are grown.
  • Chkl products having part or all of the amino acid sequence set out in SEQ ID NO: 2 or SEQ ID NO.: 4 are contemplated.
  • Use of mammalian host cells is expected to provide for such post-translational modifications (e.g., myristoylation, glycosylation, truncation, lipidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention.
  • the enzyme products of the invention may be full length polypeptides, fragments or variants.
  • Variants comprise Chkl products wherein one or more of the specified (i.e., naturally encoded) amino acids is deleted or replaced or wherein one or more nonspecified amino acids are added: (1) without loss of the protein kinase activity specific to Chkl; or (2) with disablement of the protein kinase activity specific to Chkl; or (3) with disablement of the ability to interact with members or regulators of the cell cycle checkpoint pathway.
  • Substrates of Chkl and proteins which interact with Chkl may be identified by various assays.
  • Substrates of Chkl may be identified by incorporating test compounds in assays for kinase activity.
  • Chkl kinase is resuspended in kinase buffer and incubated either in the presence or absence of the test compound (e.g., myelin basic protein, casein, histone HI, or appropriate substrate peptide).
  • the amount of phosphate transferred by the kinase to the test compound are measured by autoradiography or scintillation counting. Transfer of phosphate to the test compound is indicative that the test compound is a substrate of the kinase.
  • Yet another aspect of this invention provides a diagnostic assay for detecting and quantifying the presence of Chkl in a biological sample.
  • a biological sample suspected of comprising Chkl is utilized in a kinase assay.
  • the presence of Chkl is identified by the phosphorylation of a substrate protein, e.g. myelin b protein, or the detection of a self-phosphorylated product.
  • the phosphorylated product of the kinase reaction can be detected by for example, autoradiography or scintillation counting.
  • Interacting proteins may be identified by the following assays.
  • a first assay contemplated by the invention is a two-hybrid screen.
  • the two-hybrid system was developed in yeast [Chien et al., Proc. Natl. Acad. Sci. USA, 88: 9578-9582 (1991)] and is based on functional in vivo reconstitution of a transcription factor which activates a reporter gene.
  • a polynucleotide encoding a protein that interacts with Chkl is isolated by: transforming or transfecting appropriate host cells with a DNA construct comprising a reporter gene under the control of a promoter regulated by a transcription factor having a DNA binding domain and an activating domain; expressing in the host cells a first hybrid DNA sequence encoding a first fusion of part or all of Chkl and either the DNA binding domain or the activating domain of the transcript ion factor; expressing in the host cells a library of second hybrid DNA sequences encoding second fusions of part or all of putative Chkl binding proteins and the DNA binding domain or activating domain of the transcription factor which is not incorporated in the first fusion; detecting binding of an Chkl interacting protein to Chkl in a particular host cell by detecting the production of reporter gene product in the host cell; and isolating second hybrid DNA sequences encoding the interacting protein from the particular host cell.
  • a lexA promoter to drive expression of the reporter gene, the lacZ reporter gene, a transcription factor comprising the lexA DNA binding domain and the GAL4 transactivation domain, and yeast host cells.
  • Other assays for identifying proteins that interact with Chkl may involve immobilizing Chkl or a test protein, detectably labeling the nonimmobilized binding partner, incubating the binding partners together and determining the amount of label bound. Bound label indicates that the test protein interacts with Chkl.
  • Another type of assay for identifying Chkl interacting proteins involves immobilizing Chkl or a fragment thereof on a solid support coated (or impregnated with) a fluorescent agent, labeling a test protein with a compound capable of exciting the fluorescent agent, contacting the immobilized Chkl with the labeled test protein, detecting light emission by the fluorescent agent, and identifying interacting proteins as test proteins which result in the emission of light by the fluorescent agent.
  • the putative interacting protein may be immobilized and Chkl may be labeled in the assay.
  • antibody products e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, CDR-grafted antibodies and antigen-binding fragments thereof
  • binding proteins such as those identified in the assays above
  • Binding proteins can be developed using isolated natural or recombinant enzymes. The binding proteins are useful, in turn, for purifying recombinant and naturally occurring enzymes and identifying cells producing such enzymes.
  • Assays for the detection and quantification of proteins in cells and in fluids may involve a single antibody substance or multiple antibody substances in a "sandwich" assay format to determine cytological analysis of Chkl protein levels.
  • binding proteins are also manifestly useful in modulating (i.e., blocking, inhibiting, or stimulating) enzyme/substrate or enzyme/regulator interactions.
  • Anti-idiotypic antibodies specific for mammalian checkpoint kinase binding proteins are also contemplated.
  • Chkl protein levels are low or absent in AT patients
  • Chkl levels can be used as a marker in the development of compounds that inhibit Atm function. Because expression of Chkl in AT cells is low or non-existent, inhibition of Atm function should decrease Chkl expression. This decrease can be monitored by examining the expression levels of Chkl.
  • the invention contemplates that mutations in the Chkl gene that result in loss of normal function of the Chkl gene product underlie human disease states in which failure of a cell cycle checkpoint is involved. Gene therapy to restore Chkl activity would thus be indicated in treating those disease states (for example, testicular cancer).
  • Chkl gene Delivery of a functional Chkl gene to appropriate cells is effected in vivo or ex vivo by use of viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus) or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments).
  • viral vectors e.g., adenovirus, adeno-associated virus, or a retrovirus
  • physical DNA transfer methods e.g., liposomes or chemical treatments.
  • Antisense nucleic acids preferably 10 to 20 base pair oligonucleotides capable of specifically binding to Chkl expression control sequences or Chkl RNA are introduced into cells (e.g., by a viral vector or colloidal dispersion system such as a liposome).
  • the antisense nucleic acid binds to the Chkl target sequence in the cell and prevents transcription or translation of the target sequence.
  • Phosphothioate and methylphosphate antisense oligonucleotides are specifically contemplated for therapeutic use by the invention.
  • the antisense oligonucleotides may be further modified by poly-L-lysine, transferrin polylysine, or cholesterol moieties at their 5 end.
  • Checkpoint signal transduction results in transcriptional regulation.
  • transcriptional regulation is MyoD muscle regulation. Chkl expression suppresses the ability of MyoD to induce muscle gene transcription and suppresses the ability of MyoD to induce myogenesis (see Example 7). It is contemplated that another aspect of this invention is to regulate Chkl levels in order to effect the differentiation and proliferation of stem cells such as those involved in muscle proliferation.
  • Agents that modulate Chkl protein kinase activity may be identified by incubating a test compound with Chkl immunopurified from cells naturally expressing the mammalian checkpoint protein kinase, with Chkl obtained from recombinant procaryotic or eukaryotic host cells expressing the enzyme, or with purified Chkl, and then determining the effect of the test compound on Chkl protein kinase activity.
  • the activity of the checkpoint protein kinase can be measured by determining the amount of
  • the amount of phosphate incorporated into the substrate is measured by scintillation counting or autoradiography. An increase in the amount of phosphate transferred to the substrate in the presence of the test compound compared to the amount of phosphate transferred to the substrate in the absence of the test compound indicates that the test compound is an activator of the Chkl protein kinase.
  • a decrease in the amount of phosphate transferred to the substrate in presence of the test compound compared to the moles of phosphate transferred to the substrate in the absence of the test compound indicates that the modulator is an inhibitor of the Chkl protein kinase.
  • a Chkl -specific antibody linked to agarose beads is incubated with a cell lysate prepared from host cells expressing the protein kinase. The beads are washed to remove proteins binding nonspecifically to the beads and the beads are then resuspended in kinase buffer. The reaction is initiated by the addition of gamma-32P-ATP and an appropriate exogenous substrate such as lipid or peptide. The activity of the protein kinase is measured by determining the moles of 32P -phosphate transferred either to the protein kinase itself or the added substrate.
  • the host cells lack endogenous Chkl and/or ATM protein kinase activity.
  • the selectivity of a compound that modulates the protein kinase activity of Chkl can be evaluated by comparing its activity on Chkl to its activity on other known mammalian checkpoint protein kinases.
  • the combination of the recombinant Chkl products of the invention with other recombinant mammalian checkpoint kinase products in a series of independent assays provides a system for developing selective modulators of Chkl.
  • combinatorial libraries, peptide and peptide mimetics, defined chemical entities, oligonucleotides, and natural product libraries may be screened for activity as modulators in assays such as those described below.
  • an assay for identifying modulators of Chkl kinase activity involves incubating a Chkl protein kinase preparation in kinase buffer with gamma-32P-ATP and an exogenous kinase substrate, both in the presence and absence of a test compound, and measuring the amount of phosphate transferred to the substrate.
  • An increase in the amount of phosphate transferred to the substrate in presence of the test compound compared to the amount of phosphate transferred to the substrate in the absence of the test compound indicates that the test compound is an activator of the Chkl kinase.
  • a decrease in the amount of phosphate transferred to the substrate in presence of the test compound compared to the amount of phosphate transferred to the substrate in the absence of the test compound indicates that the modulator is an inhibitor of said Chkl protein kinase.
  • assays for identifying compounds that modulate interaction of Chkl with other proteins may involve: transforming or transfecting appropriate host cells with a DNA construct comprising a reporter gene under the control of a promoter regulated by a transcription factor having a DNA-binding domain and an activating domain; expressing in the host cells a first hybrid DNA sequence encoding a first fusion of part or all of Chkl and the DNA binding domain or the activating domain of the transcription factor; expressing in the host cells a second hybrid DNA sequence encoding part or all of a protein that interacts with Chkl and the DNA binding domain or activating domain of the transcription factor which is not incorporated in the first fusion; evaluating the effect of a test compound on the interaction between Chkl and the interacting protein by detecting binding of the interacting protein to Chkl in a particular host cell by measuring the production of reporter gene product in the host cell in the presence or absence of the test compound; and identifying modulating compounds as those test compounds altering production of the reported gene product in comparison to production of the test compound
  • Another type of assay for identifying compounds that modulate the interaction between Chkl and an interacting protein involves immobilizing Chkl or a natural Chkl interacting protein, detectably labeling the nonimmobilized binding partner, incubating the binding partners together and determining the effect of a test compound on the amount of label bound wherein a reduction in the label bound in the present of the test compound compared to the amount of label bound in the absence of the test compound indicates that the test agent is an inhibitor of Chkl interaction with protein. Conversely, an increase in the binding in the presence of the test compound compared to the amount label bound in the absence of the compound indicates that the putative modulator is an activator of Chkl interaction with the protein.
  • Yet another method contemplated by the invention for identifying compounds that modulate the binding between Chkl and an interacting protein involves immobilizing Chkl or a fragment thereof on a solid support coated (or impregnated with) a fluorescent agent, labeling the interacting protein with a compound capable of exciting the fluorescent agent, contacting the immobilized Chkl with the labeled interacting protein in the presence and absence of a test compound, detecting light emission by the fluorescent agent, and identifying modulating compounds as those test compounds that affect the emission of light by the fluorescent agent in comparison to the emission of light by the fluorescent agent in the absence of the test compound.
  • the Chkl interacting protein may be immobilized and Chkl may be labeled in the assay.
  • Chkl modulators of Chkl may affect its protein kinase activity, its localization in the cell, and/or its interaction with members of the cell cycle checkpoint pathway.
  • Chkl modulators may be formulated in compositions comprising pharmaceutically acceptable carriers. Such compositions may additionally include chemotherapeutic agents. Dosage amounts indicated would be sufficient to result in modulation of Chkl activity in vivo.
  • Selective modulators may include, for example, polypeptides or peptides which specifically bind to Chkl or Chkl nucleic acid, oligonucleotides which specifically bind to Chkl or Chkl nucleic acid, and/or other non-peptide compounds (e.g., isolated or synthetic organic molecules) which specifically react with Chkl or Chkl nucleic acid. Mutant forms of Chkl which affect the enzymatic activity or cellular localization of wild-type Chkl are also contemplated by the invention.
  • Example 1 details the isolation of polynucleotides encoding mammalian Chkl kinases and chromosomal mapping of the human Chkl DNA.
  • Example 2 describes the recombinant expression of DNAs encoding mammalian Chkl .
  • Example 3 describes the preparation of antibodies to Chkl. Northern blots showing tissue and cell distribution of Chkl are described in Example 4.
  • Example 5 reports the results of immunohistological and western blot studies of Chkl expression.
  • Example 6 describes biochemical and biological activities of murine Chk 1.
  • Example 1 Isolation of Human Chkl cDNA
  • ChklHu cDNA was identified by screening EST sequences for similarity to S. pombe Chkl .
  • An EST (H67490) with homology to the COOH-terminus of Chkl was identified and cloned and used to build a contig showing limited homology to the COOH-terminal 120 amino acids. This contig was extended by RACE PCR to give a clone of 1735bp. The RACE PCR fragment was used to probe cDNA libraries to generate the final sequence.
  • the full length human Chkl cDNA was subcloned into pGEMT.
  • the plasmid containing the full length human cDNA is identified as pGEMT-ChklHU pGEMT-ChklHU was deposited with American Type Culture Collection, 12301 Parklawn Drive, Rockville, MX 20852 on date 27th August 1997 under Accession No.
  • the full length cDNA and deduced amino acid sequences of human Chkl are provided in SEQ ID NOs. : 2 and 4 respectively.
  • the full length DNA and deduced amino acid sequences of human Chkl are provided in SEQ LD NOs.: 1 and 2, respectively.
  • ChklMo was identified by library screening of a mouse testis cDNA library using a degenerate human Chkl specific probe.
  • the partial cDNA and deduced amino acid sequences of mouse Chkl (ChklMu) are provided in SEQ ID NO.: 3 and 4, respectively.
  • the ChklHu and ChklMu cDNAs encode a protein of approximately 70 kD.
  • the kinase domain of ChklHu is 161 to 264 of SEQ ID NO.: 2.
  • the kinase domain of ChklMu comprises amino acids 1 to 61 of SEQ LD NO.: 4.
  • Figure 1 compares the amino acid sequences of Chkl homologs from human, mouse, C. elegans, S. pombe and S. cerevisiae.
  • amino acid residues identical among all species are boxed.
  • Roman numerals indicate subdomains conserved among the homologs.
  • Subdomains V through IX comprise the substrate recognition site and contain the greatest frequency of conserved residues. This is determined by homology with other known kinases (Hanks et al., Science 241 :42-52, 1988).
  • a mouse genomic clone encoding Chkl was obtained using PCR screening of a PI mouse 129 library.
  • the PCR primers used to screen the mouse 129 pi library were mmChk2 (ACG TGG ACA AAC TGG TTC AGG) (SEQ ID NO. : 5) and mmChk 21: CTG ATA GCC CAA CTT CTC GAA SEQ LD NO.: 6). These primers were used to generate an amplicon of 208 bp corresponding to nucleotide X to X of SEQ LD NO.: 4. The amplicon was used to identify a clone of approximately 81-100 kb.
  • An EcoRl restriction digest of the genomic clone was performed and the restriction products were subcloned into a vector with zeocin as the selectable marker. The vector was obtained from Invitrogen p. zero 1.1 (2.8 kb).
  • the Eco RI restriction digests were resolved on a 0.8% agarose gel and transferred to nitrocellulose according to standard procedures.
  • the nitrocellulose blot was probed with a 208bp amplicon to confirm that a genomic clone was identified.
  • the Stanford G3 Radiation Hybrid panel was used to map the location of Chkl.
  • PCR reactions using two oligonucleotides in the 3' untranslated region of the human cDNA library derived Chkl DNA fragment yielded a unique PCR amplicon with primer l(Chkl 30mer3'UT) GGCTCTGGGGAATCCTGGTGAATATAGTGCTGC (SEQ ID NO.: 7 and primer 2 (Chkl 30mer 3'UT)
  • TCCCCTGAAACTTGGTTTCCACCAGATGAG SEQ LD NO. 8.
  • ChklHu localized to marker Dl 154610 which has been mapped to the telomeric region of 11 q at 23.3. This region has been identified as the site of tumor suppressor genes implicated in ovarian, breast, lung, colon and cervix cancer and melanoma. [Gabra et al., Cancer Research, 56:950-954 (1996)].
  • DNA encoding Chkl glutathione-S-transferase fusion protein (GST-ChklHu) was also prepared.
  • a DNA encoding GST-ChklHu was cloned into pGEX KGH using Ndel Sail restriction sites introduced into ChklHu. The internal Nde I sites were eliminated by silent mutagenesis.
  • E. coli F Dh5a transformed with GST-Chkl were used to prepare recombinant proteins.
  • 5mM LPTG was added and cells were grown for four hours at 37 C. The culture was harvested and washed in STE buffer (lOmM Tris pH 8, 150 mM NaCl, and lmM EDTA).
  • the cells were resuspended in 6 mol STE with lmM PMSF and lOOmg lysozyme. The cultures were incubated on ice for fifteen minutes, and 5 mM DTT and 1.5% Sarkosyl was added and the cells were sonicated. The debris was pelleted, and the supernatant was made to 2% Triton X-100. Glutathione agarose beads were added and the beads were pelleted in a benchtop centrifuge and bound proteins were eluted with elution buffer (50mM Tris pH
  • Kinase assays were performed by incubating GST-ChklHu in kinase buffer (25M HEPES, pH 7.7; 50 mM KC1; 10 mM MgC12; 0.1% NP-40; 2% glycerol; lmM DTT, 50uM ATP) with or without lmg os substrate protein, and incubated in kinase buffer containing lOmCi [g-32P] ATP (3000 Ci mmol) for twenty minutes at 37 C. The reactions were stopped with 20 ul 2 X SDS sample buffer prior to separation on 6% PAGE. Kinase reactions were then transferred to Immobilon, exposed to film, then subsequently probed to detect precipitated protein.
  • kinase buffer 25M HEPES, pH 7.7; 50 mM KC1; 10 mM MgC12; 0.1% NP-40; 2% glycerol; lmM DTT, 50uM ATP
  • the glutathione affinity purified fusion was able to autophosphorylate and phosphorylate substrate proteins such a s myeline basic protein showing that Chkl is active as a protein kinase, independent of regulatory subunits.
  • Antibodies specific for mammalian Chkl proteins were generated as follows.
  • the coupled resin was loaded into an econo column (Bio Rad) (Hercules, California) and was washed with 10 column volumes of TEB.
  • the resin was treated blocking buffer (50 mM cysteine in TEB buffer per ml of gel) and was sequentially washed with 20 column volumes of salt buffer.
  • the column was washed with 20 column volumes of salt buffer (500 mM NaCI in 50 mM NaH2PO4, pH 6.5) and 10 column volumes of phosphate buffer (50 mM NaH2PO4, pH 6.5 ). Twenty mis of rabbit serum was loaded onto the column and was washed with 10 column volumes of salt buffer and the antibody was eluted with glycine buffer (lOOmM Glycine-HCL, pH 2.5).
  • Chkl #2-3 was able to immunoprecipitate mouse Chkl protein from mouse testes extract as described in Example 6.
  • aChkl#2-3 recognized recombinant human Chkl and the ChklHu glutathione-S-transferase fusion protein expressed in E. coli.
  • Monoclonal antibodies are prepared by immunizing Balb/c mice subcutaneously with Chkl, Gst-Chkl or a Chkl fragment in complete Freund's adjuvant (CFA). Subsequent immunizations in CFA or incomplete Freund's adjuvant is performed to increase immune response.
  • CFA complete Freund's adjuvant
  • the spleen of the immunized animal is removed aseptically and a single-cell suspension is formed by grinding the spleen between the frosted ends of two glass microscope slides submerged in serum free RPMI 1640, supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 mg/ml streptomycin (RPMI) (Gibco, Canada).
  • the cell suspension is filtered through sterile 70-mesh Nitex cell strainer (Becton Dickinson, Parsippany, New Jersey), and washed twice by centrifuging at 200 g for 5 minutes and resuspending the pellet in 20 ml serum free RPMI.
  • Thymocytes taken from naive Balb/c mice are prepared in the same manner.
  • Two x 108 spleen cells are combined with 4 x 107 NS-1 cells (kept in log phase in RPMI with 11% fetal bovine serum (FBS) for three days prior to fusion), centrifuged and the supernatant is aspirated.
  • the cell pellet is dislodged and 2 ml of 37 C PEG 1500 (50% in 75 mM HEPES, pH 8.0) (Boehringer Mannheim) is added while stirring over the course of one minute, followed by the addition of 14 ml of serum free RPMI over seven minutes. Additional RPMI can be added and the cells are centrifuged at 200 g for 10 minutes.
  • the pellet After discarding the supernatant, the pellet is resuspended in 200 ml RPMI containing 15% FBS, 100 mM sodium hypoxanthine, 0.4 mM aminopterin, 16 mM thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer Mannheim) and 1.5 x 106 thymocytes/ml.
  • the suspension is dispensed into ten 96-well flat bottom tissue culture plates (Corning, United Kingdom) at 200 ml/well.
  • Cells are fed on days 2, 4, and 6 days post-fusion by aspirating 100 ml from each well with an 18 G needle (Becton Dickinson), and adding 100 ml/well plating medium containing 10 U/ml IL-6 and lacking thymocytes.
  • ELISAs are performed as follows. Immulon 4 plates (Dynatech, Cambridge, Massachusetts) are coated at 4 C with 50 ml/well with lOOng/well of Chkl in 50 mM carbonate buffer, pH 9.6. Plates are washed with PBS with 0.05%, Tween 20 (PBST) and blocked 30 minutes at 37 C with 0.5% Fish Skin Gelatin. Plates are washed as described above and 50 ml culture supernatant is added. After incubation at 37 C for 30 minutes, 50 ml of horseradish peroxidase conjugated goat anti-mouse IgG(fc) (Jackson ImmunoResearch, West Grove, Pennsylvania) [diluted 1 : 10,000 in PBST] is added.
  • Plates are incubated at 37 C for 30 minutes, washed with PBST and 100 ml of substrate, consisting of 1 mg/ml TMB (Sigma) and 0.15ml/ml 30% H2O2 in 100 mM Citrate, pH 4.5, is added. The color reaction is stopped with the addition of 50 ml of 15% H2SO4. A450 is read on a plate reader (Dynatech).
  • GTTGAGACTCCATCATCAAGG SEQ ID NO.: 9
  • the conditions for PCR were as follows: One cycle of eight minutes at 94 °C then forty cycles of 94 °C for twenty seconds, 58 °C for twenty seconds, 72 °C for twenty seconds. The products were analyzed on a 4% agarose gel. The amplicons were labeled with 32P-ATP for Northern analysis.
  • a nylon membrane containing 2mg of size fractionated poly (A)+ RNA from human and mouse tissue sources including human heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes, and mouse heart, brain, spleen, lung, liver, skeletal muscle, kidney, and testis (Clonetech Laboratories, Palo Alto, California) was probed with the labeled amplicons as recommended by the manufacturer except that the final wash was performed at 55° C to minimize the possibility of cross-hybridization to related sequences.
  • RNA samples from both mouse and human show approximately two to four fold higher levels of RNA expression than other tissues.
  • ChklMo protein was examined by immunohistological characterization of cross-sections of mouse testes.
  • pre-meiotic cells surround the surface of the seminiferous tubule and progression towards the interior lumen of the tubule corresponds to progressively later stages of meiosis and sperm maturation [Moens et al., J. Histochem. Cytochem, 25:480 (1977)].
  • mice Both wildtype and mutant mice were tested and analyzed by immunohistochemistry using aChkl#2-3, a polyclonal antibody.
  • Six micron cryosections were placed in a 50 C oven to dry and fixed in 4 C acetone for two minutes.
  • the slides were incubated with aChkl#2-3 antisera at a 1 : 100 dilution for thirty minutes.
  • the secondary, goat anti-rabbit biotinylated antibody was applied to each section at a dilution of 1 :200 and incubated for fifteen minutes at 37 C.
  • the tertiary antibody, goat anti biotin was applied to each section at a dilution of 1 :200 and incubated for fifteen minutes at 37 C. After each incubation, the slides were rinsed with 1 X TBS. DAB horseradish-peroxidase substrate was used to detect positive signal in the samples. The reaction was stopped in water and counterstained with Gill's Hematoxylin.
  • testes of ChklMo, atm+/+ p53+/+ (A), atm+/+ p53+/- (B) atm-/- p53+/+ (C), atm-/- p53+/- (D), and, atm-/- p53-/- (E) were immunohistologically characterized using anti-Chkl antiserum.
  • Testes cryosections were stained with affinity-purified anti-Chkl antiserum (aChkl #2-3) and with an anti-ATR monoclonal
  • ChklMo shows temporal increases and decreases in nuclear staining in normal mice. ChklMo is most highly expressed at pachynema in primary spermatocytes, indicating that ChklMo may act downstream of Atr function during meiotic prophase, after Atr, which acts earlier during zygonema.
  • Atm and p53 have checkpoint properties and may act at an earlier phase in signaling relative to ChklHu/Mo
  • the localization of ChklMo by histological analyzes was examined in atm-/-p53+/+, atm-/-p53-/- and atm-/-p53+/- mice [Done hower et al., Nature, 356:215 (1992); Kuerbitz et al., Proc. Natl. Acad. Sci. USA, 89:7491 (1992);
  • ChklMo accumulation and localization was independent of p53 status but dependent on Atm, suggesting that ChklMo also acts downstream of Atm in meiotic prophase.
  • Chkl in mammalian meiosis, the temporal and spatial distribution of Chkl in surface spread preparations of spermatocytes was determined.
  • spermatocytes For the meiotic preparations, surface spreads of spermatocytes from fifteen to twenty-one day old mice (C57-bl/6) were prepared and antibody incubation and detection procedures were preformed as described in Ashley et al., Chromosoma, 104: 19 (1995). Antibody incubation and detection procedures were a modification of the protocol of Moens et al. as described previously in Ashley et al. Since the antibodies against Chkl and Sep3 (control) were both raised in rabbit, spermatocytes were labeled and imaged sequentially. Goat-anti rabbit IgG-rhodamine-conjugated and goat-anti rabbit IgG-FITC-conjugated (Pierce) secondary antibodies were used for detection.
  • Chkl is present along the synaptonemal complexes (SC) of synapsed homologous chromosomes. Chromosomes that are in the process of synapsing have Chkl staining, but no staining is observed on the unsynapsed axial elements As meiosis proceeds into pachynema, ChklMo remains associated with autosomal synaptonemal complexes in a focal staining pattern similar to ATM
  • a pachytene spermatocyte was labeled with both anti-Chkl and a mouse monoclonal antibody against Atr (224C) Although Chkl initially appears in a focal pattern, in pachynema Chkl seems to accumulate along the SCs In addition, Chkl foci appear along the unsynapsed axial elements of the X and Y chromosomes in mid pachynema where it colocalizes with Atr Chkl remains on the SCs throughout pachynema and disappears when the homologous chromosomes disassociate in diplonema Progression of meiotic prophase I appears to be normal in p53-/- mice In an early pachytene spermatocyte labeled for Chkl and Scp3, Chkl is present along the SCs and the synapsed region of the sex chromosomes However, Chkl does not appear along the unsynapsed axial element of the X chromosome in early pachytene In atm-/- mice,
  • Chkl appears in a focal pattern along the synaptonemal complexes of synapsing homologous chromosomes in zygonema, in a pattern similar to that of Atm Chkl accumulates along the SCs as meiosis progresses into pachynema, and by mid-pachynema Chkl coats the entire SCs In early pachynema,
  • Chkl is present along the synapsed region of the XY bivalent
  • Chkl foci also appear along the unsynapsed axes of both the X and Y chromosomes, where it colocalizes with Atr Atr is found in foci along the unsynapsed axes of the sex chromosomes early, and later coats the entire X and Y axes throughout pachynema
  • Meiosis appears to be unaffected in p53 deficient mice, as is demonstrated by histological analysis and immuno staining of surface spread spermatocytes with Scp3 and Chkl
  • atm-/- mice are sterile as the result of progressive fragmentation of meiotic chromosomes following synapsis, leading to apoptosis
  • Immunolocalization of Chkl in atm-/- spermatocytes indicates a lack of Chkl on the SCs, suggesting a role of Chkl downstream of Atm in mammalian meiosis
  • Western analysis of testes extracts was performed according to Keegan et al., Genes Dev., 10:2423 (1996).
  • Chkl protein was present in an Atm-dependent fashion, suggesting that synthesis or stability of ChklMo depends on the Atm protein. MTE of mice lacking Atm did not stain for Chkl indicating that atm-1- mice did not express Chkl . In contrast, MTE of wild type mouse or from mice in which p53 expression was disrupted showed Chkl staining.
  • Example 6 The kinase activity of mouse Chkl and its ability to associate with Atr were also demonstrated.
  • Antibody aChkl#2-3 also used to immunoprecipitate Chkl from mouse testes extract (MTE). Approximately 30 decapsulated testes were ground in a mortar with liquid nitrogen and the grounds were transferred to a 15 ml dounce homogenizer. Fifteen mis of lysis buffer (50mM NaPO4, pH 7.2, 0.5% TritonX-100, 2mM EDTA, 2mM EGTA, 25mM NaF, 25mM 2-glycerophosphate, lmM phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml.
  • lysis buffer 50mM NaPO4, pH 7.2, 0.5% TritonX-100, 2mM EDTA, 2mM EGTA, 25mM NaF, 25mM 2-glycerophosphate, lmM phenylmethylsulfonyl fluoride (PMSF)
  • leupeptin 1 mg/ml pepstatin A, and 2mM DTT was added and the extract was dounced 30 times with a loose pestle and 20 times with a tight pestle. After a low speed spin, the supernatant assayed using BCA for protein concentration determination.
  • the immune-complex bound slurry was washed three times in TSAT and one time with kinase buffer (25uM HEPES, pH 7.7; 50 mM KC1; 10 mM MgC12; 0.1% NP-40; 2% glycerol; lmM DTT, 50uM ATP), and incubated in kinase buffer containing lOmCi [g-32P] ATP (3000 Ci mmol) for twenty minutes at 37 C. The reactions were stopped with 20 ul 2 X SDS sample buffer prior to separation on 6% PAGE. Kinase reactions were then transferred to Immobilon, exposed to film, then subsequently probed to detect precipitated protein.
  • kinase buffer 25uM HEPES, pH 7.7; 50 mM KC1; 10 mM MgC12; 0.1% NP-40; 2% glycerol; lmM DTT, 50uM ATP
  • Chkl and Atr can associate in meiotic cells
  • 460 mg of MTE was immunoprecipitated with anti-Atr monoclonal antibody (aAtr-224C) under conditions as described above.
  • the Atr immunoprecipitate was electrophoresed on a 6% or 8% PAGE, electroblotted onto immoblin P membrane and was probed with anti-Chkl antibody (aChkl #2-3).
  • the blots showed that Chkl co-precipitates with Atr indicating that Atr and Chkl associate in meiotic cells.
  • the Chkl that immunoprecipitates with Atr was able to self phosphorylate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne d'une manière générale des gènes codant des protéines associées à la kinase point de contrôle du cycle cellulaire essentielles à la méiose, à la mitose et aux réactions à la détérioration de l'ADN dans des cellules, ainsi que des protéines respectives. Ces kinases arrêtent le cycle cellulaire suite à la détérioration de l'ADN afin de permettre la réparation de l'ADN avant la mitose, la méiose ou le début de la réplication de l'ADN. Plus particulièrement, l'invention concerne une nouvelle kinase point de contrôle du cycle, Chk1, et des séquences polynucléotidiques codant Chk1. L'invention concerne également des dosages permettant d'identifier des modulateurs de Chk1. Ces modulateurs sont utiles, notamment, en chimiothérapie et comme adjuvants de rayonnement.
PCT/US1998/018558 1997-09-05 1998-09-04 Materiels de proteine-kinase point de controle du cycle cellulaire, effecteur de chk1 mammalien et methodes WO1999011795A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002270911A CA2270911A1 (fr) 1997-09-05 1998-09-04 Materiels de proteine-kinase point de controle du cycle cellulaire, effecteur de chk1 mammalien et methodes
AU92231/98A AU9223198A (en) 1997-09-05 1998-09-04 Mammalian chk1 effector cell-cycle checkpoint protein kinase materials and methods
JP51710899A JP2002516577A (ja) 1997-09-05 1998-09-04 哺乳動物ｃｈｋ１エフェクター細胞周期チェックポイントタンパク質キナーゼ物質及び方法
EP98944772A EP0960203A1 (fr) 1997-09-05 1998-09-04 Materiels de proteine-kinase point de controle du cycle cellulaire, effecteur de chk1 mammalien et methodes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9718952.6A GB9718952D0 (en) 1997-09-05 1997-09-05 Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
GB9718952.6 1997-09-05

Publications (1)

Publication Number Publication Date
WO1999011795A1 true WO1999011795A1 (fr) 1999-03-11

Family

ID=10818664

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/018558 WO1999011795A1 (fr) 1997-09-05 1998-09-04 Materiels de proteine-kinase point de controle du cycle cellulaire, effecteur de chk1 mammalien et methodes

Country Status (7)

Country Link
EP (1) EP0960203A1 (fr)
JP (1) JP2002516577A (fr)
CN (1) CN1254377A (fr)
AU (1) AU9223198A (fr)
CA (1) CA2270911A1 (fr)
GB (2) GB9718952D0 (fr)
WO (1) WO1999011795A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055844A2 (fr) * 1998-04-27 1999-11-04 Icos Corporation Techniques permettant de moduler la differentiation
WO2001021815A1 (fr) * 1999-09-23 2001-03-29 Rigel Pharmaceuticals, Inc. Proteines du cycle cellulaire associees a des genes points de controle, compositions et modes de mise en oeuvre
US6211164B1 (en) * 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
WO2001029210A1 (fr) * 1999-10-18 2001-04-26 Genena Ltd. Procede d'etablissement de connexions entre genes
EP1096014A2 (fr) * 1999-11-01 2001-05-02 Agouron Pharmaceuticals, Inc. Domaines catalytiques d'effecteur protéine-kinase point de contrôle du cycle cellulaire Chk1, procédés et matériaux pour l'identification d'inhibiteurs de ceux-ci
WO2001057206A2 (fr) * 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Procede et reactif destines a inhiber la checkpoint kinase-1 (chk 1)
EP1204673A2 (fr) * 1999-07-29 2002-05-15 The Wistar Institute Of Anatomy And Biology Compositions permettant d'augmenter la resistance de la sensibilite de cellules cancereuses a la tension mitotique
WO2004004785A1 (fr) * 2002-07-10 2004-01-15 Exelixis, Inc. Agents mchk modificateurs de la voie metabolique de chk1 et procedes d'utilisation
US6723498B1 (en) * 1999-06-30 2004-04-20 Millennium Pharmaceuticals, Inc. Chk1 and uses thereof
WO2005027907A1 (fr) * 2003-09-17 2005-03-31 Icos Corporation Utilisation d'inhibiteurs de la chk1 pour lutter contre la proliferation cellulaire
WO2008059069A2 (fr) * 2006-11-17 2008-05-22 Universität Duisburg-Essen Utilisation de modifications génétiques dans le gène humain chk1 codant pour la kinase point de contrôle 1
EP2330105A1 (fr) 2005-03-29 2011-06-08 ICOS Corporation Dérivés d'uree d'heteroaryle utilises pour inhiber CHK1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009433A1 (fr) * 1995-09-06 1997-03-13 Icos Corporation Genes de point de controle a cycle cellulaire
WO1997018323A2 (fr) * 1995-11-16 1997-05-22 Icos Corporation Materiaux de kinase relatifs a la phosphatidylinositol kinase du point de controle du cycle cellulaire, et procedes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009433A1 (fr) * 1995-09-06 1997-03-13 Icos Corporation Genes de point de controle a cycle cellulaire
WO1997018323A2 (fr) * 1995-11-16 1997-05-22 Icos Corporation Materiaux de kinase relatifs a la phosphatidylinositol kinase du point de controle du cycle cellulaire, et procedes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AL-KHODAIRY F ET AL: "Identification and characterization of new elements involved in checkpoint and feedback controls in fission yeast.", MOLECULAR BIOLOGY OF THE CELL, (1994 FEB) 5 (2) 147-60. JOURNAL CODE: BAU. ISSN: 1059-1524., XP002087724 *
CARR A M: "Checkpoints take the next step [comment].", SCIENCE, (1996 JAN 19) 271 (5247) 314-5. JOURNAL CODE: UJ7. ISSN: 0036-8075., XP002087726 *
FLAGGS G. ET AL.: "Atm-dependent interactions of a mammalian chk1 homolog with meiotic chromosomes.", CURRENT BIOLOGY, (1997 DEC 1) 7 (12) 977-86. JOURNAL CODE: B44. ISSN: 0960-9822., XP002087728 *
HILLIER L. ET AL.: "The WashU-Merck EST project, AC AA224307", EMBL DATABASE, 22 February 1997 (1997-02-22), Heidelberg, XP002087721 *
MARRA M. ET AL.: "The WashU-HHMI Mouse EST project, AC AA122952", EMBL DATABASE, 22 November 1996 (1996-11-22), Heidelberg, XP002087722 *
SANCHEZ Y ET AL: "Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25 [see comments].", SCIENCE, (1997 SEP 5) 277 (5331) 1497-501. JOURNAL CODE: UJ7. ISSN: 0036-8075., XP002087723 *
WALWORTH N. AND BERNARDS R.: "rad-dependent response of the chk1 -encoded protein kinase at the DNA damage checkpoint [see comments].", SCIENCE, vol. 271, 19 January 1996 (1996-01-19), pages 353 - 356, XP002087725 *
WEINERT T: "A DNA damage checkpoint meets the cell cycle engine [comment].", SCIENCE, (1997 SEP 5) 277 (5331) 1450-1. JOURNAL CODE: UJ7. ISSN: 0036-8075., XP002087727 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055844A3 (fr) * 1998-04-27 2000-04-27 Icos Corp Techniques permettant de moduler la differentiation
WO1999055844A2 (fr) * 1998-04-27 1999-11-04 Icos Corporation Techniques permettant de moduler la differentiation
US6723498B1 (en) * 1999-06-30 2004-04-20 Millennium Pharmaceuticals, Inc. Chk1 and uses thereof
EP1204673A2 (fr) * 1999-07-29 2002-05-15 The Wistar Institute Of Anatomy And Biology Compositions permettant d'augmenter la resistance de la sensibilite de cellules cancereuses a la tension mitotique
US7176293B1 (en) 1999-07-29 2007-02-13 The Wistar Institute Of Anatomy And Biology Compositions and methods to enhance sensitivity of cancer cells to mitotic stress
EP1204673A4 (fr) * 1999-07-29 2002-10-30 Wistar Inst Compositions permettant d'augmenter la resistance de la sensibilite de cellules cancereuses a la tension mitotique
WO2001021815A1 (fr) * 1999-09-23 2001-03-29 Rigel Pharmaceuticals, Inc. Proteines du cycle cellulaire associees a des genes points de controle, compositions et modes de mise en oeuvre
WO2001029210A1 (fr) * 1999-10-18 2001-04-26 Genena Ltd. Procede d'etablissement de connexions entre genes
EP1096014A2 (fr) * 1999-11-01 2001-05-02 Agouron Pharmaceuticals, Inc. Domaines catalytiques d'effecteur protéine-kinase point de contrôle du cycle cellulaire Chk1, procédés et matériaux pour l'identification d'inhibiteurs de ceux-ci
EP1096014A3 (fr) * 1999-11-01 2002-09-25 Agouron Pharmaceuticals, Inc. Domaines catalytiques d'effecteur protéine-kinase point de contrôle du cycle cellulaire Chk1, procédés et matériaux pour l'identification d'inhibiteurs de ceux-ci
KR100431564B1 (ko) * 1999-11-01 2004-05-22 아구론 파마슈티컬스, 인크. 인간 효과인자 세포 사이클 체크포인트 단백질 키나제의 촉매활성 도메인과, 그 억제제를 위한 물질 및 그억제제의 확인 방법
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
WO2001057206A2 (fr) * 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Procede et reactif destines a inhiber la checkpoint kinase-1 (chk 1)
WO2001057206A3 (fr) * 2000-02-03 2002-08-29 Ribozyme Pharm Inc Procede et reactif destines a inhiber la checkpoint kinase-1 (chk 1)
WO2001068837A2 (fr) * 2000-03-10 2001-09-20 Abbott Laboratories Oligonucleotides antisens du gene chk1 humain et leurs utilisations
WO2001068837A3 (fr) * 2000-03-10 2002-04-04 Abbott Lab Oligonucleotides antisens du gene chk1 humain et leurs utilisations
US6211164B1 (en) * 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
WO2004004785A1 (fr) * 2002-07-10 2004-01-15 Exelixis, Inc. Agents mchk modificateurs de la voie metabolique de chk1 et procedes d'utilisation
WO2005027907A1 (fr) * 2003-09-17 2005-03-31 Icos Corporation Utilisation d'inhibiteurs de la chk1 pour lutter contre la proliferation cellulaire
EP2330105A1 (fr) 2005-03-29 2011-06-08 ICOS Corporation Dérivés d'uree d'heteroaryle utilises pour inhiber CHK1
WO2008059069A2 (fr) * 2006-11-17 2008-05-22 Universität Duisburg-Essen Utilisation de modifications génétiques dans le gène humain chk1 codant pour la kinase point de contrôle 1
WO2008059069A3 (fr) * 2006-11-17 2008-09-12 Univ Duisburg Essen Utilisation de modifications génétiques dans le gène humain chk1 codant pour la kinase point de contrôle 1
US9074259B2 (en) 2006-11-17 2015-07-07 Universitat Duisburg-Essen Use of genetic modifications in human gene CHK1 which codes for checkpoint kinase 1

Also Published As

Publication number Publication date
GB9718952D0 (en) 1997-11-12
GB9723231D0 (en) 1998-01-07
JP2002516577A (ja) 2002-06-04
AU9223198A (en) 1999-03-22
EP0960203A1 (fr) 1999-12-01
CN1254377A (zh) 2000-05-24
CA2270911A1 (fr) 1999-03-11

Similar Documents

Publication Publication Date Title
US7189802B2 (en) Integrin-linked kinase and its uses
EP1073723B1 (fr) Proteines kinases apparentees a la famille de ste20
US20070202107A1 (en) Novel kinases
JP2003501038A (ja) 蛋白質キナーゼ
JP2002508937A (ja) Ａｕｒ１および／またはａｕｒ２関連疾患の診断および治療
US8114975B2 (en) Protein tyrosine kinase substrate LAT and its use in the identification of (ANT) agonists of the kinase
WO1999011795A1 (fr) Materiels de proteine-kinase point de controle du cycle cellulaire, effecteur de chk1 mammalien et methodes
JP2004504009A (ja) 新規ヒト蛋白質キナーゼおよび蛋白質キナーゼ様酵素
WO1999066051A2 (fr) Kinases en rapport avec nek et avec bub1
US6958238B2 (en) Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof
CA2404971A1 (fr) Nouvelles proteine kinases humaines et nouvelles enzymes de type proteine kinase
JP2003527824A (ja) ポリペプチドおよび核酸をシグナリングする新規細胞
JP2001157590A (ja) 紫外線照射仲介皮膚損傷に関連する遺伝子およびポリヌクレオチド並びにそれらの使用
US7217551B1 (en) ATM releated kinase ATX, nucleic acids encoding same and methods of use
US6699983B1 (en) Integrin-linked kinase and its uses
US6593098B1 (en) Genes encoding proteins involved in mitotic checkpoint control and methods of use thereof
US20020090703A1 (en) Mammalian protein phosphatases
US20060188974A1 (en) Human protein kinases and protein kinase-like enzymes
US20030211989A1 (en) Novel human protein kinases and protein kinase-like enzymes
MXPA99004132A (en) Mammalian chk1 effector cell-cycle checkpoint protein kinase materials and methods
US6617427B1 (en) Nucleic acid molecule encoding an ankyrin repeat TVL-1 protein and methods of use thereof
US20050084877A1 (en) Mammalian protein phosphatases
US20020098514A1 (en) Protein-protein interactions
WO2001098524A2 (fr) Interactions proteine-proteine
JP2003144168A (ja) 核外移行機能又は核−細胞質間移行機能を有する細胞周期関連タンパク質

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98801676.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2270911

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004132

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 92231/98

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998944772

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09297653

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998944772

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998944772

Country of ref document: EP